Mubadala Investment Company’s Acquisition of KELIX Bio’s operations in Egypt and Morocco

Lead party: Mubadala Investment Company (lead investor/buyer)Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed). Target: KELIX Bio Limited (private company) · Sector: Healthcare, Pharmaceuticals · Countries of operation: Morocco, Egypt Transaction type: Merger/Acquisition(M&A), Exit · Asset class: Private Equity · Strategy: Buyout · Instrument: Equity · Equity stake: 1% ·…


Lead party: Mubadala Investment Company (lead investor/buyer)

Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed).

Target: KELIX Bio Limited (private company) · Sector: Healthcare, Pharmaceuticals · Countries of operation: Morocco, Egypt

Transaction type: Merger/Acquisition(M&A), Exit · Asset class: Private Equity · Strategy: Buyout · Instrument: Equity · Equity stake: 1% · Fund: African Development Partners II (ADP II)

Lead investor/buyer: Mubadala Investment Company · Investors/buyers: Mubadala Investment Company · Sellers: Development Partners International (DPI), European Bank for Reconstruction and Development (EBRD), British International Investment (BII)

Legal advisers: not identified in the source record.

Source: announced 25 March 2024. Original announcement: dpi-llp.com.